Drug Profile


Alternative Names: tICAM; tICAM-rhinovirus; tICAM453; truncated ICAM-1

Latest Information Update: 09 Oct 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Class Antivirals
  • Mechanism of Action Selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Rhinovirus infections

Most Recent Events

  • 09 Oct 2006 Discontinued - Clinical-Phase-Unknown for Rhinovirus infections in USA (Intranasal)
  • 16 May 2001 Profile reviewed but no significant changes made
  • 16 May 2001 Investigation in Rhinovirus infections in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top